The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1574
ISSUE1574
June 17, 2019
Drugs for Psoriasis
| Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Drugs for Psoriasis
June 17, 2019 (Issue: 1574)
Mild to moderate psoriasis can be treated with topical
drugs or with phototherapy. Patients with moderate to
severe disease generally require systemic therapy.
- MB Hoffman et al. Psoriasis during pregnancy: characteristics and important management recommendations. Expert Rev Clin Immunol 2015; 11:709.
- Calcipotriene for psoriasis. Med Lett Drugs Ther 1994; 36:70.
- Calcipotriene/betamethasone foam (Enstilar) for psoriasis. Med Lett Drugs Ther 2016; 58:48.
- Calcitriol (Vectical) for mild to moderate plaque psoriasis. Med Lett Drugs Ther 2009; 51:70.
- DM Pariser et al. Halobetasol 0.01%/tazarotene 0.045% lotion in the treatment of moderate-to-severe plaque psoriasis: maintenance of therapeutic effect after cessation of therapy. J Drugs Dermatol 2018; 17:723.
- A Menter et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol 2009; 60:643.
- A Dattola et al. Update of calcineurin inhibitors to treat inverse psoriasis: A systematic review. Dermatol Ther 2018; 31:e12728.
- DC Butler et al. Safety of dermatologic medications in pregnancy and lactation. Part II: lactation. J Am Acad Dermatol 2014; 70:417.
- X Chen et al. Narrow-band ultraviolet B phototherapy versus broad-band ultraviolet B or psoralen-ultraviolet A photochemotherapy for psoriasis. Cochrane Database Syst Rev 2013; 10:CD009481.
- MB Totonchy and MW Chiu. UV-based therapy. Dermatol Clin 2014; 32:399.
- E Sbidian et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev 2017; 12: CD011535.
- RB Warren et al. An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017; 389:528.
- ED Dommasch et al. Risk of serious infection in patients receiving systemic medications for the treatment of psoriasis. JAMA Dermatol 2019 May 10 (epub).
- VM Heydendael et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 2003; 349:658.
- I Flytström et al. Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial. Br J Dermatol 2008; 158;116.
- Inhibitors and inducers of CYP enzymes and P-glycoprotein. Med Lett Drugs Ther 2017 September 18 (epub). Available at: medicalletter.org/downloads/CYP_PGP_Tables.pdf.
- K Papp et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol 2015; 73:37.
- C Paul et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol 2015; 173:1387.
- K Reich et al. Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study. J Eur Acad Dermatol Venereol 2018; 32:397.
- A Menter et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol 2019; 80:1029.
- A Egeberg et al. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Br J Dermatol 2018; 78:509.
- IH Kim et al. Comparative efficacy of biologics in psoriasis: a review. Am J Clin Dermatol 2012; 13:365.
- B Gottlieb et al. Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2). J Am Acad Dermatol 2018; 79:302.
- RE Kalb et al. Risk of serious infection with biologic and systemic treatment of psoriasis: results from the psoriasis longitudinal assessment and registry (PSOLAR). JAMA Dermatol 2015; 151:961.
- AL Semble et al. Safety and tolerability of tumor necrosis factor-α inhibitors in psoriasis: a narrative review. Am J Clin Dermatol 2014; 15:37.
- L Hsu et al. Antidrug antibodies in psoriasis: a systematic review. Br J Dermatol 2014; 170:261.
- Ustekinumab (Stelara) for psoriasis. Med Lett Drugs Ther 2010; 52:7.
- KA Papp et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371:1675.
- CE Griffiths et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010; 362:118.
- KA Papp et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol 2013; 168:844.
- Secukinumab (Cosentyx) for psoriasis. Med Lett Drugs Ther 2015; 57:45.
- Ixekizumab (Taltz) – a second IL-17A inhibitor for psoriasis. Med Lett Drugs Ther 2016; 58:59.
- Brodalumab (Siliq) – another IL-17A antagonist for psoriasis. Med Lett Drugs Ther 2017; 59:118.
- M Lebwohl et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med 2015; 373:1318.
- J Bagel et al. Secukinumab is superior to ustekinumab in clearing skin in patients with moderate to severe plaque psoriasis (16-week CLARITY results). Dermatol Ther (Heidelb) 2018; 8:571.
- K Reich et al. Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study. Br J Dermatol 2017; 177:1014.
- RG Langley et al. Secukinumab in plaque psoriasis – results of two phase 3 trials. N Engl J Med 2014; 371:326.
- CE Griffiths et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet 2015; 386:541.
- A Deodhar et al. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res Ther 2019; 21:111.
- KA Papp et al. Infections from seven clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasis. Br J Dermatol 2017; 177:1537.
- A Chiricozzi et al. No meaningful association between suicidal behavior and the use of IL-17A-neutralizing or IL-17RA-blocking agents. Expert Opin Drug Saf 2016; 15:1653.
- Guselkumab (Tremfya) for psoriasis. Med Lett Drugs Ther. 2017; 59:179.
- Tildrakizumab (Ilumya) – another IL-23 antagonist for psoriasis. Med Lett Drugs Ther 2019; 61:4.
- Risankizumab (Skyrizi) – a new IL-23 antagonist for plaque psoriasis. Med Lett Drugs Ther 2019; 61:81.
- A Blauvelt et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol 2017; 76:405.
- RG Langley et al. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial. Br J Dermatol 2018; 178:114.
- K Reich et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol 2017; 76:418.
- K Reich et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet 2017; 390:276.
- KB Gordon et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet 2018; 392:650.
- K Reich et al. Efficacy and safety of continuous risankizumab or switching from adalimumab to risankizumab treatment in patients with moderate-to-severe plaque psoriasis: results from the phase 3 IMMvent trial. American Academy of Dermatology Annual Meeting, Washington, DC, March 1-5, 2019. Poster 10218.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Drugs for Psoriasis
Article code: 1574a
Article code: 1574a
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.